The investigators also demonstrated that tipifarnib induced selective anti-tumor activity, with HRAS wild-type tumors growing progressively on tipifarnib treatment but HRAS mutant tumors being highly sensitive to tipifarnib when compared to control groups. The gene discussed is HRAS; the disease is neoplasm.